Repository logo
 

Systematic E2 screening reveals a UBE2D-RNF138-CtIP axis promoting DNA repair.


Change log

Authors

Schmidt, Christine K 
Sczaniecka-Clift, Matylda 
Coates, Julia 
Jhujh, Satpal 

Abstract

Ubiquitylation is crucial for proper cellular responses to DNA double-strand breaks (DSBs). If unrepaired, these highly cytotoxic lesions cause genome instability, tumorigenesis, neurodegeneration or premature ageing. Here, we conduct a comprehensive, multilayered screen to systematically profile all human ubiquitin E2 enzymes for impacts on cellular DSB responses. With a widely applicable approach, we use an exemplary E2 family, UBE2Ds, to identify ubiquitylation-cascade components downstream of E2s. Thus, we uncover the nuclear E3 ligase RNF138 as a key homologous recombination (HR)-promoting factor that functions with UBE2Ds in cells. Mechanistically, UBE2Ds and RNF138 accumulate at DNA-damage sites and act at early resection stages by promoting CtIP ubiquitylation and accrual. This work supplies insights into regulation of DSB repair by HR. Moreover, it provides a rich information resource on E2s that can be exploited by follow-on studies.

Description

Keywords

Carrier Proteins, Cell Cycle, Cell Line, Tumor, Cell Survival, DNA Breaks, Double-Stranded, Endodeoxyribonucleases, Green Fluorescent Proteins, HEK293 Cells, Humans, Immunoblotting, Microscopy, Confocal, Nuclear Proteins, RNA Interference, Recombinational DNA Repair, Ubiquitin-Conjugating Enzymes, Ubiquitin-Protein Ligases, Ubiquitination

Journal Title

Nat Cell Biol

Conference Name

Journal ISSN

1465-7392
1476-4679

Volume Title

17

Publisher

Springer Science and Business Media LLC
Sponsorship
Cancer Research Uk (None)
European Research Council (268536)
Wellcome Trust (092096/Z/10/Z)
Cancer Research Uk (None)
Alex Sossick, Nicola Lawrence and Richard Butler. Research in the S.P.J. lab is funded by Cancer Research UK Program Grant C6/A11224, the European Research Council (DDREAM), the European Community Seventh Framework Programme grant agreement no. HEALTH-F2- 2010-259893 (DDResponse). Core infrastructure funding was provided by Cancer Research UK Grant C6946/A14492 and Wellcome Trust Grant WT092096. S.P.J. receives a salary from the University of Cambridge, supplemented by Cancer Research UK. C.K.S. was funded by a FEBS Return-to-Europe fellowship. P.B. is supported by the Emmy Noether Programme of the German Research Foundation (DFG, BE 5342/1-1).